Zepbound is FDA-approved tirzepatide: a reviewed label, a verified dose in every pen or vial, and a manufacturer legally accountable if something goes wrong. Compounded tirzepatide is a copy made by a pharmacy that FDA has never evaluated for safety, quality or effectiveness. Since FDA determined the tirzepatide shortage was resolved, the legal footing for mass-producing copies is gone — and Lilly's own cash-pay prices have shrunk the gap that made compounding tempting in the first place.
If you are reading this because a telehealth ad quoted you a number that looked like a rescue, that reaction is reasonable. This page is not here to shame the impulse. It is here to tell you precisely what is inside each purchase, what is known and unknown about each, and what to ask before you hand over a card. We are not telling you to start, stop or switch anything — that decision belongs to you and your prescriber.
The regulatory situation, in plain terms
Compounding pharmacies are legitimate and old. They exist to make something a specific patient needs that the commercial product cannot provide — a dye-free version, a different concentration for a child, a preservative-free preparation. What the law does not allow is compounding what is "essentially a copy" of an approved, commercially available drug. There is one big exception: when a drug is on FDA's shortage list, that restriction relaxes.
That exception is what built the compounded GLP-1 industry. Tirzepatide went into shortage, and pharmacies were allowed to fill the hole. Then the hole closed. FDA determined the tirzepatide shortage was resolved and, after a compounder trade group sued and forced a re-evaluation, reaffirmed that finding in a declaratory order dated December 19, 2024. FDA then set explicit wind-down windows: state-licensed 503A pharmacies had 60 days, expiring February 18, 2025, and 503B outsourcing facilities had 90 days, expiring March 19, 2025 (FDA, checked July 13, 2026). After those dates, compounding essentially-a-copy of tirzepatide is exposed to enforcement.
So what is still being sold? Two different things, and it matters a great deal which one you are being offered. A 503A pharmacy may still compound tirzepatide for a named patient when the prescriber documents a clinical need the approved product genuinely does not meet. That lane is narrow. What is not permitted is batch-producing tirzepatide copies for a marketing funnel — and that is what much of the online market still looks like. FDA issued warning letters to 30 telehealth companies on February 20, 2026, announcing the action on March 3, 2026; the letters singled out claims implying the compounded product is the same as the approved drug, and websites that brand a vial with the seller's own trademark while obscuring who actually compounded it (FDA press announcement). Another batch of warning letters to telehealth and weight-loss sellers followed in June 2026 and is posted in FDA's warning-letter database. This is not a settled market. It is one under active enforcement.
Eli Lilly, which holds the approved product, has been loud and litigious: open letters to patients and prescribers, and lawsuits against med spas, wellness centers and sellers it says misled people into believing they were buying a Lilly medicine. A manufacturer defending its franchise is not a neutral witness, and you should read its statements with that in mind. But FDA's position is independent of Lilly's, and it points the same direction.
Side by side: what you are actually buying
| What matters | Zepbound (FDA-approved) | Compounded tirzepatide |
|---|---|---|
| FDA review | Reviewed for safety, effectiveness and manufacturing quality; approved in 2023 for weight management, and later for moderate-to-severe obstructive sleep apnea in adults with obesity | None. FDA does not review compounded drugs for safety, effectiveness or quality before they are sold |
| Potency and purity | Every unit made to a filed, inspected specification | Depends entirely on the pharmacy and its ingredient source. FDA has flagged unapproved salt forms and impurity concerns in the compounded GLP-1 market |
| What's in it | Tirzepatide plus the excipients on the label — nothing else | Some sellers add vitamin B12, glycine, pyridoxine, niacinamide or carnitine. None have evidence of benefit in this context, and none were studied with tirzepatide |
| How it's supplied | Single-dose pens, single-dose vials, single-patient-use KwikPen — dose fixed per unit | Usually a multi-dose vial plus syringes; the patient measures the dose, often in "units" rather than milligrams |
| Dosing-error risk | Lower: the device or single-dose unit delivers the prescribed amount | Higher. FDA has received adverse-event reports, including hospitalizations, tied to dosing errors with compounded GLP-1s — patients and clinicians miscalculating a dose from a vial and syringe |
| If something goes wrong | Named manufacturer, mandatory adverse-event reporting, recall machinery | No manufacturer accountability. Recalls depend on the pharmacy; the seller may be a marketing brand that never discloses who compounded it |
| Legal footing today | Fully approved, in supply | Copies of the approved drug are no longer permitted post-shortage; patient-specific compounding for a documented clinical need is the remaining lane |
The dosing-error problem is not theoretical
The single most under-discussed difference in that table is the delivery format. An approved pen or single-dose vial hands you one dose. A compounded multi-dose vial hands you a liquid and a syringe and asks you to do arithmetic — and the arithmetic is frequently expressed in syringe "units" rather than milligrams, which is where the decimal point goes to die. FDA has documented adverse-event reports from compounded GLP-1s that include hospitalizations after dosing errors, with patients and in some cases clinicians miscalculating the amount to draw. A tenfold error is not exotic when the conversion is being done at a kitchen table.
One quiet reason this matters for women at midlife: if you are also managing thyroid medication, HRT or blood-pressure drugs, a dosing error does not land in isolation. It lands on top of everything else.
The added-ingredients problem
This is the part most comparison pages skip. "Tirzepatide + B12" is marketed as a bonus — an energy boost bundled in. In an open letter dated March 12, 2026, Lilly said its own laboratory testing of compounded products combining tirzepatide with B12 variants (methylcobalamin, hydroxocobalamin, cyanocobalamin) detected significant levels of an impurity formed by a chemical reaction between the two, with no characterized safety profile, and that it had asked FDA to recall compounded GLP-1 products containing untested additives. Lilly is an interested party. But the underlying logic does not depend on who says it: nobody has run a study on that reaction product — its absorption, its toxicity, its effect on receptor binding, its long-term consequences. If you inject it, you are the study.
The same applies to glycine, carnitine, pyridoxine and the rest. There is no trial showing they improve weight outcomes when injected alongside tirzepatide, and no stability data most buyers can see. The approved product contains what it contains because that formulation is what was tested.
The cost counterpoint — and why it is weaker than it was
The honest case for compounded tirzepatide was always money. When the approved product's list price ran past $1,000 a month and insurers refused to cover weight-loss drugs, a few hundred dollars from an online clinic was the difference between treatment and none. That gap was real, and pretending otherwise would be dishonest.
It is much smaller now, and this is the single most useful practical fact on this page: Lilly sells Zepbound directly for cash. On Lilly's own savings and self-pay pages (checked July 13, 2026), self-pay pricing is listed as $299/month for 2.5 mg, $399/month for 5 mg, and $449/month for 7.5 mg through 15 mg, for a one-month supply (Lilly defines a month as 28 days) of single-dose vials or a single-patient-use KwikPen.
Those prices carry conditions you should read before you build a budget around them. The most important is refill timing: Lilly's terms require the refill purchase within 45 days of the previous delivery to hold the self-pay price. Miss that window and the standard self-pay price applies — Lilly's terms list $499 for 7.5 mg and $699 for the 10 mg through 15 mg doses. The offer terms also carry an expiration date, and this program has been repriced more than once since it launched. Check Lilly's page yourself on the day you buy; any price on any website, including this one, is a snapshot.
Compare that with what compounded programs advertise. We are not going to print a compounded price as fact, because those prices are set by individual sellers, change constantly, and are frequently quoted as a promotional first month that expires. What we can say honestly is the shape of it: the spread that used to be roughly $200 against $1,000+ is now, for many people, a difference of tens to low hundreds of dollars a month against a product that has a reviewed label, a fixed-dose device and a manufacturer behind it. That is a different trade than the one the market was built on.
If you are commercially insured and your plan covers Zepbound, the manufacturer savings card can go further: Lilly's page describes fills as little as $25 for a 1-, 2- or 3-month prescription for eligible commercially insured patients whose plan covers the product, subject to a maximum annual benefit. People enrolled in Medicare, Medicaid, TRICARE, VA or any other government healthcare program are not eligible for manufacturer copay cards. That is a federal rule, not a technicality — it cannot be worked around, and you should not attempt to.
Run your own numbers before you decide anything: our cost and coverage estimator walks through what your plan is likely to do and what the cash routes cost.
What the label says about dosing — and what it does not authorize
Dosing on this page is reference, not instruction. Your prescriber sets your dose. The FDA-approved Zepbound label (via DailyMed) publishes a starting dose of 2.5 mg once weekly for 4 weeks, increases in 2.5 mg steps no sooner than every 4 weeks, maintenance doses of 5, 10 or 15 mg once weekly, and a maximum of 15 mg weekly. The label also describes what to do about a missed dose in terms of a defined window, and skipping the dose otherwise.
That is the published schedule of the approved product. It is not a plan for you, and it is emphatically not a template to reproduce with a vial and a syringe. Do not self-adjust your dose. Do not stretch, split or ration doses to save money. Do not double up after a missed dose. Take every one of those questions to your prescriber, who can see your history and the rest of your medication list.
Zepbound also carries a boxed warning about thyroid C-cell tumors observed in rodents, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. More on what to expect in tirzepatide side effects and the GLP-1 dosing schedule explained.
How to evaluate an online provider without being sold to
We do not name telehealth companies as recommendations, here or anywhere. Evaluate one yourself, with these five questions:
- Am I being prescribed the FDA-approved product, or a compounded preparation? Ask for the answer in writing.
- If compounded: which licensed pharmacy compounds it, in which state, and what is the documented clinical reason the approved product will not work for me?
- Does the product contain anything besides tirzepatide? If yes, what, and on what evidence?
- Is there a real prescriber I can reach with a side effect at week six — or only a chat widget?
- What does my price become after the introductory month?
A provider that answers all five plainly is a different animal from one that answers none. Our guide to choosing GLP-1 care online goes further.
When to talk to your prescriber
Book a conversation — do not decide alone — if any of these apply. You are currently using a compounded product and are unsure what is in the vial or how the dose is measured. You have severe or persistent abdominal pain, especially radiating to the back, or persistent vomiting: these can signal pancreatitis and warrant urgent care. You have a personal or family history of medullary thyroid carcinoma or MEN 2. You take insulin or a sulfonylurea, where hypoglycemia risk changes. You have gallbladder symptoms, planned surgery or anesthesia, diabetic retinopathy, or significant kidney disease. You have been denied coverage and are considering a cash route: bring the denial letter, ask for the specific reason code, and ask what your plan requires. Your plan writes those rules and we cannot know them from here. Ask directly: "What exactly do you need documented for this to be approved?"
Related: Mounjaro vs Zepbound (same drug, different label), Zepbound vs Wegovy, GLP-1s and muscle loss, and weight and metabolism.
Disclosure: VidaBeacon may earn a commission from some links to care or products elsewhere on this site. No company paid for placement in this article, and no telehealth provider, pharmacy or seller is recommended here. Prices and regulatory dates were checked against FDA and Lilly sources on July 13, 2026 and can change without notice. Nothing on this page is medical advice, or an instruction to start, stop or change any medication.
